Citadel Advisors
OKUR

Citadel Advisors’s OnKure Therapeutics OKUR Stock Holding History

Citadel Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-310
Closed -$5.15K – 15629
2024
Q1 		$5.15K Sell
310
-2,290
-88% -$37.8K ﹤0.01% 13763
2023
Q4 		$41.6K Buy
2,600
+2,580
+12,900% +$161K ﹤0.01% 11980
2023
Q3 		$1.52K Buy
+20
New +$1.36K ﹤0.01% 13850

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors's OKUR Position: Q1 2026 in Review

Citadel Advisors reduced its OnKure Therapeutics (OKUR) stake by 83% in Q1 2026, selling an estimated $573K and leaving 37,587 shares worth $156K. The position accounts for ﹤0.01% of the portfolio, ranked #11650.

Citadel Advisors first reported a position in OKUR in Q2 2022 and has held it in 14 quarters since. The position peaked at $8.78M in Q4 2024. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Citadel Advisors held 37,587 shares of OnKure Therapeutics worth $156K as of Q1 2026.
  • Citadel Advisors sold 185,538 OnKure Therapeutics shares in Q1 2026, an estimated $573K.
  • OnKure Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11650 holding.
  • Citadel Advisors first reported a position in OnKure Therapeutics in Q2 2022 and has held it in 14 quarters since.
  • Citadel Advisors's OnKure Therapeutics position peaked at $8.78M in Q4 2024.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.